Antipsychotic Medication Adherence and Diabetes-Related Hospitalizations Among Medicaid Recipients With Diabetes and Schizophrenia
Abstract
Objective:
This cross-sectional study examined the relationship between antipsychotic medication adherence and preventable diabetes-related hospitalizations for individuals with diabetes and schizophrenia.
Methods:
Hospitalizations related to diabetes, an ambulatory care sensitive condition, were assessed among Medicaid recipients in New York State with comorbid diabetes and schizophrenia (N=14,365) for three levels of antipsychotic medication adherence: very low to no engagement (two or fewer prescriptions or none in first 6 months), moderate to low adherence, and adherent (proportion of days covered ≥80%).
Results:
Rates of preventable diabetes hospitalization were highest among individuals with very low to no engagement in antipsychotic treatment (4.7%), followed by those with moderate to low adherence (3.3%). Diabetes hospitalizations among adherent individuals were comparable with those of the total diabetes population (both 2.0%). The odds of a preventable diabetes hospitalization were significantly higher among individuals with very low to no engagement in antipsychotic treatment (adjusted odds ratio [AOR]=2.42) and among those with moderate to low adherence (AOR=1.57) than among adherent individuals. Black individuals were also at increased risk of a preventable diabetes hospitalization after the analyses adjusted for antipsychotic adherence and other variables (AOR=1.38).
Conclusions:
This study indicates a relationship between antipsychotic adherence and improved diabetes outcomes among individuals with schizophrenia. Engagement in mental health treatment may be a critical path toward improving health disparities for individuals with schizophrenia. Individuals with very low to no engagement were a particularly vulnerable group, and the exclusion of persons with less than two prescriptions from research and quality measures should be revisited.
HIGHLIGHTS
•
Among individuals with schizophrenia and diabetes, those who had the highest level of antipsychotic adherence had the best diabetes outcomes, and those with the lowest level of antipsychotic adherence had the poorest diabetes outcomes.
•
Individuals with schizophrenia and diabetes who were antipsychotic adherent had rates of preventable diabetes hospitalization that were comparable to those of the total diabetes population.
•
Black individuals were more likely than individuals of other race-ethnicities to have a preventable diabetes hospitalization independent of antipsychotic medication adherence.
•
Results of this study suggest that improving engagement in antipsychotic treatment among individuals with schizophrenia and diabetes could reduce preventable diabetes-related hospitalizations.
Antipsychotic medication adherence has been linked to critical psychiatric outcomes in schizophrenia. Low adherence to antipsychotic medication among individuals with schizophrenia has been associated with relapse; poor functional outcomes and prognosis; lower quality of life and life satisfaction; and increased emergency room visits, hospitalization, and suicide (1–13). Moreover, relapse and rehospitalization due to low adherence to medication are linked to increased patient cost (1–3).
Although antipsychotic medication is the foundation for pharmacological management of schizophrenia (4, 5), these medications can have significant metabolic side effects, including weight gain, hyperglycemia, and diabetes (6–9). The iatrogenic effects of antipsychotics may compound the risk of diabetes resulting from the onset of schizophrenia itself (10). Antipsychotics may both increase the incidence of diabetes and have adverse impacts on glucose control among those who have diabetes (6, 11). There is also some evidence that individuals with schizophrenia are at increased risk of poor medical outcomes after they develop diabetes. A study of the Nationwide Inpatient Database found that individuals with a comorbid diagnosis of schizophrenia were more likely to have a diabetes-related hospitalization (12).
Alternatively, antipsychotic adherence may have some benefits for general medical outcomes. Although symptoms associated with mental health conditions may impede diabetes self-management (13) and lead to a greater risk of medical rehospitalization (14, 15), antipsychotic adherence is associated with greater psychiatric stability, which may allow individuals to manage their health better. Stability of mental health conditions may be particularly important for diabetes because of the level of self-care required, including careful monitoring of dietary intake, glucose checks, and often complex medication regimens.
In a study of Medicaid beneficiaries with schizophrenia, individuals who adhered to their antipsychotic medication had fewer medical and psychiatric hospitalizations and, consequently, lower costs of care (16). A national study in Taiwan found that individuals with schizophrenia and type 2 diabetes who regularly used antipsychotic medication were less likely to have diabetes-related complications than those with no antipsychotic medication treatment (17). However, because of conflicting reports in the literature, the relationship between antipsychotic adherence and health outcomes remains unclear. Antipsychotic medications have been linked to increased risk of premature mortality (18), with some contested studies finding the opposite effect (19–22).
A better understanding of the relationship between antipsychotic adherence and diabetes outcomes for individuals with schizophrenia is needed to guide patient education and clinical decision making. Moreover, an examination of adherence and preventable diabetes hospitalizations may inform the development of successful adherence interventions. In the current study, we used a national measure of quality developed by the Agency for Healthcare Research and Quality to identify diabetes-related hospitalizations that may have been prevented given adequate primary care in the community. We examined the risk of preventable diabetes-related hospitalizations among individuals with schizophrenia, by the level of antipsychotic medication adherence, in a large state Medicaid program.
Methods
Data Source
The data source was New York State (NYS) Medicaid inpatient, outpatient, and pharmacy claim and encounter records extracted from the Office of Health Insurance Programs Medicaid DataMart. Data extraction and analysis were conducted from 2013 to 2016. Medicaid claims and encounters are administrative data; no medical record review was conducted for this study. Approval for this study was granted by the NYS Department of Health Institutional Review Board; this study was exempt from obtaining informed consent. Demographic characteristics are available for almost all NYS Medicaid recipients because such information is collected at the time of enrollment; status changes, such as those for payer and aid category, are updated frequently. Claim and encounter records include primary and up to 25 additional diagnoses classified by ICD-9-CM code; primary and up to 25 additional procedure codes; primary and up to five additional revenue codes; state-specific rate codes; and prescription drug codes classified by National Drug Codes (NDCs).
Study Population
Individuals included in our study population were ages 18–64 with prevalent diabetes mellitus (type 1 or type 2) and schizophrenia and were continuously enrolled in Medicaid for the calendar year 2012. Diabetes was defined according to the 2013 Healthcare Effectiveness Data and Information Set (HEDIS) criteria, which specifies that an enrollee must have had one inpatient visit, or two outpatient visits, with a diagnosis of diabetes or pharmacy claims for drugs used to treat diabetes during the measurement year (2012) or the year prior (2011) (23). Individuals were identified as having schizophrenia if they had an Episode Diagnostic Category indicating schizophrenia during the measurement year (2012) (24, 25). To identify prevalent cases in which an individual had both diabetes and schizophrenia, individuals had to meet criteria for diabetes and schizophrenia diagnoses in the measurement year as well as the year prior to the measurement year (2011 and 2012). Our continuous Medicaid enrollment criteria allowed for up to a 1-month gap in enrollment during the measurement year. We excluded individuals who had Medicare at any point in the year.
More than 219,651 Medicaid recipients were identified as having diabetes in 2012, and of those, 191,521 were identified with prevalent diabetes (87.2%). Among those with prevalent diabetes, 14,365 individuals with prevalent schizophrenia were identified for this investigation.
Study Variables
The proportion of individuals with one or more preventable diabetes-related hospitalizations was the primary outcome. The Agency for Healthcare Research and Quality created a set of prevention quality indicators, including four diabetes-related measures, to identify hospitalizations that may have been prevented with adequate primary care in the community (26). All four diabetes-related prevention measures were used to create our composite outcome measure, including short-term diabetes complications, long-term diabetes complications, uncontrolled diabetes, and lower extremity amputation (26). Individuals met criteria for the outcome composite variable if they had one or more preventable diabetes-related hospitalizations during the calendar year 2012.
In this study, the demographic characteristics of interest included age, race, Medicaid payer type, and receipt of Supplemental Security Income (SSI). Age group and race categories were dichotomized. Age groups were divided into those younger than age 45 and those age 45 and older. Race-ethnicity was dichotomized into black and non-black categories because of small cell sizes. The non-black category included members identified as American Indian-Alaska Native, Asian-Pacific Islander, Hispanic, white, and other race-ethnicity. The Medicaid payer and disability status categories were also dichotomized into Medicaid managed care and fee-for-service and those who received SSI and those who did not (non-SSI), respectively.
Our primary exposure variable, adherence to antipsychotic medications, was constructed as three categories based on examination of claims data: adherent, moderate to low adherence, and very low to not engaged in antipsychotic treatment. Adherence group definitions were based on HEDIS specifications for the Antipsychotic Medication Adherence for Persons With Schizophrenia measure (23). In brief, Medicaid claims and encounter data were used to identify antipsychotic prescriptions, dispense date, and days’ supply for all antipsychotic prescriptions filled. For long-acting injectable antipsychotics, medication-specific standard days’ supply was used, consistent with HEDIS specifications (23). The proportion of days covered (PDC) by an antipsychotic was calculated from the date of the first filled outpatient antipsychotic prescription during the year of observation through the end of the year.
Adherent individuals were defined as those with schizophrenia who had a PDC of ≥80%, and the first prescription filled must have been within the first 180 days of the year. Individuals with moderate to low adherence were defined as those with an antipsychotic PDC of <80%, but who had a minimum of two prescriptions, with one or more filled during the first 180 days of the year. Individuals with very low to no engagement were defined as those with less than two antipsychotic prescriptions filled during the measurement year, or with no antipsychotic prescriptions filled in the first 180 days of the measurement year. Although these individuals did not meet minimum inclusion criteria for the HEDIS measure, they were included in this study as the group with the lowest level of antipsychotic adherence.
Data Analysis
We performed a cross-sectional analysis of our study population during the calendar year 2012. Bivariate analyses were conducted to examine differences in demographic characteristics among the three groups (adherent, moderate to low adherence, and very low to no engagement) in our study population. Demographic variables significantly associated with antipsychotic adherence or preventable diabetes-related hospitalizations in the bivariate analyses (p<0.05) were included in the multivariable models. In addition, although the chi-square p value for payer (fee-for-service or Medicaid managed care) was not significant, we believe that there are meaningful differences between these two subpopulations, and therefore, we opted to include the variable in the adjusted logistic regression model.
We estimated the likelihood of a preventable diabetes-related hospitalization given the level of adherence to antipsychotic medication among individuals with diabetes and schizophrenia. A corresponding model among the same population adjusted for age (younger than age 45 or age 45 and older), race-ethnicity (black or non-black), sex (male or female), and payer (fee-for-service or Medicaid managed care) was also run by using logistic regression. Aid category (SSI or non-SSI) was considered for this model but was excluded because of small cell sizes. We used SAS, version 9.4, for all statistical analyses (27).
Results
In our study population of individuals with prevalent schizophrenia and diabetes, 33.3% were younger than age 45, 56.6% were female, 31.6% were black, 78.5% were enrolled in a Medicaid-managed care plan, and 79.2% were receiving SSI benefits (Table 1). One-third (33%, N=4,747) of the study population was classified as antipsychotic adherent, 13% (N=1,914) as having moderate to low adherence, and more than half (54%, N=7,704) as having very low or no engagement in antipsychotic treatment.
| Study population (diabetes and schizophrenia) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Diabetes population (N=191,521) | Total (N=14,365) | Adherent (N=4,747) | Moderate to low adherence (N=1,914) | Very low to no engagement (N=7,704) | |||||||
| Characteristic | N | % | N | % | N | % | N | % | N | % | pb |
| Age group | <.001 | ||||||||||
| <45 | 43,449 | 22.7 | 4,778 | 33.3 | 1,064 | 22.4 | 515 | 26.9 | 3,199 | 41.5 | |
| ≥45 | 148,072 | 77.3 | 9,587 | 66.7 | 3,683 | 77.6 | 1,399 | 73.1 | 4,505 | 58.5 | |
| Sex | <.001 | ||||||||||
| Female | 109,476 | 57.2 | 8,129 | 56.6 | 2,468 | 52.0 | 949 | 49.6 | 4,712 | 61.2 | |
| Male | 82,045 | 42.8 | 6,236 | 43.4 | 2,279 | 48.0 | 965 | 50.4 | 2,992 | 38.8 | |
| Race-ethnicity | .001 | ||||||||||
| Black | 39,489 | 20.6 | 4,545 | 31.6 | 1,592 | 33.5 | 853 | 44.6 | 2,100 | 27.3 | |
| Non-black | 152,032 | 79.4 | 9,820 | 68.4 | 3,155 | 66.5 | 1,061 | 55.4 | 5,604 | 72.7 | |
| Payer | .901 | ||||||||||
| FFSc | 17,710 | 9.3 | 3,090 | 21.5 | 1,024 | 21.6 | 322 | 16.8 | 1,744 | 22.6 | |
| MMCd | 173,811 | 90.8 | 11,275 | 78.5 | 3,723 | 78.4 | 1,592 | 83.2 | 5,960 | 77.4 | |
| Aid categorye | <.001 | ||||||||||
| Non-SSI | 120,361 | 62.8 | 2,993 | 20.8 | 335 | 7.1 | 256 | 13.4 | 2,402 | 31.2 | |
| SSI | 71,160 | 37.2 | 11,327 | 78.9 | 4,412 | 92.9 | 1,658 | 86.6 | 5,302 | 68.8 | |
| Preventable diabetes hospitalization in 2012 | 3,881 | 2.0 | 525 | 3.7 | 97 | 2.0 | 63 | 3.3 | 365 | 4.7 | <.001 |
a
The study population included individuals ages 18–64 who were diagnosed as having prevalent diabetes mellitus (type 1 or type 2) and schizophrenia and who were continuously enrolled in Medicaid in New York State for the calendar year 2012. The diabetes population met criteria for diabetes in 2011 or 2012.
b
Reflects difference in the study population by adherence level (chi-square test).
c
Fee for service.
d
Medicaid managed care.
e
SSI, Supplemental Security Income.
All three groups of individuals within our study population (adherent, moderate to low adherence, or very low to no engagement in antipsychotic treatment) were significantly different from one another across all demographic categories (p<0.001; Table 1). Medication-adherent individuals with schizophrenia had a diabetes-related hospitalization rate similar to the total prevalent diabetes population (both 2.0%), whereas proportions were elevated for both the moderate- to low-adherence group and the very low– to no-engagement group (3.3% and 4.7%), respectively.
Within our study population, individuals with moderate to low adherence and those with very low or no engagement in antipsychotic treatment during the measurement year were significantly more likely to experience a preventable diabetes-related hospitalization compared with those who were adherent to their antipsychotic medications (Table 2). These relationships to antipsychotic adherence persisted after the analyses controlled for age, sex, race, and payer (Table 2). We also found that black individuals were significantly more likely than other racial-ethnic groups to experience a preventable diabetes-related hospitalization, even after the analyses adjusted for antipsychotic adherence and other factors (Table 2). Younger adults (<45 ) were more likely than older adults to have a preventable diabetes-related hospitalization, but age was no longer statistically significant after the analyses controlled for lower antipsychotic adherence in this group and other factors.
| Recipients with at least 1 diabetes-related hospitalization | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Variable | Recipients (N) | N | N per 10,000 population | OR | 95% CI | p | AORa | 95% CI | p |
| Antipsychotic adherence | |||||||||
| Adherent (reference) | 4,747 | 97 | 204 | ||||||
| Moderate to low adherence | 1,914 | 63 | 329 | 1.63 | 1.18–2.25 | .003 | 1.57 | 1.14–2.17 | .006 |
| Very low to no adherence | 7,704 | 365 | 474 | 2.38 | 1.90–2.99 | <.001 | 2.42 | 1.92–3.05 | <.001 |
| Age group | |||||||||
| <45 | 4,778 | 200 | 419 | 1.25 | 1.04–1.49 | .017 | 1.11 | .93–1.34 | .250 |
| ≥45 (reference) | 9,587 | 325 | 339 | ||||||
| Sex | |||||||||
| Female | 8,129 | 285 | 351 | .91 | .76–1.08 | .278 | .85 | .71–1.01 | .071 |
| Male (reference) | 6,236 | 240 | 385 | ||||||
| Race-ethnicity | |||||||||
| Black | 4,545 | 195 | 429 | 1.29 | 1.08–1.54 | .006 | 1.38 | 1.15–1.66 | .001 |
| Non-black (reference) | 9,820 | 330 | 336 | ||||||
| Payer | |||||||||
| MMCb | 11,275 | 394 | 349 | .82 | .67–1.00 | .051 | .84 | .69–1.03 | .097 |
| FFS (reference)c | 3,090 | 131 | 424 | ||||||
a
Adjusted odds ratio.
b
Medicaid managed care.
c
Fee for service.
Discussion
Consistent with previous research, in the current study, individuals with comorbid schizophrenia and diabetes had a higher prevalence of preventable diabetes hospitalizations than the total Medicaid population with diabetes (12, 28, 29). Our findings extend previous research in two important ways. First, we identified an inverse relationship between antipsychotic adherence and risk of a preventable diabetes hospitalization: individuals with the lowest level of antipsychotic adherence had the highest prevalence of diabetes hospitalizations, followed by individuals with moderate to low adherence. The hospitalization rate among individuals who were adherent to their antipsychotic treatment, on the other hand, was comparable to that of the total diabetes population. Second, the individuals with schizophrenia and diabetes with very low to no engagement in antipsychotic treatment, and therefore who did not meet inclusion criteria for measures of antipsychotic adherence used nationally for quality measurement (23), represented more than half of the study sample and had the highest rates of preventable diabetes-related hospitalizations.
This study suggests that for individuals with schizophrenia and diabetes, antipsychotic adherence improves diabetes outcomes despite the well-established association between antipsychotic medications and increased risk of metabolic concerns, including diabetes (6, 30, 31). This finding is particularly promising given that individuals with serious mental illness have higher medical morbidity and mortality than the general population, with worse outcomes for diabetes and other chronic medical conditions (32, 33). Several interventions have been developed to improve diabetes outcomes for individuals with serious mental illness (34–36). The current study suggests that antipsychotic adherence may be a modifiable risk factor for preventable diabetes hospitalization for individuals with schizophrenia; however, additional study is needed to explore these results further and to inform interventions.
A logic model may be useful to summarize a possible explanation for the relationship between antipsychotic adherence and preventable diabetes hospitalizations and can create a framework for future study. Among individuals with schizophrenia, antipsychotic adherence leads to better control of psychiatric symptoms, which may create the capacity for improved diabetes self-care and better engagement in diabetes treatment, leading to improved diabetes outcomes including decreased risk of preventable hospitalization. Antipsychotic adherence is associated with reduced psychiatric symptoms and lower relapse rates for schizophrenia (37); it stands to reason that uncontrolled psychotic symptoms would make it more challenging for individuals to engage in the complex self-care routines required for management of diabetes, including managing the timing and content of meals, testing blood sugars, and adjusting medication.
It is possible that the findings are due in part to the “healthy adherer effect,” in which adherence to any medication may be an indicator of other healthy behaviors (38). Further research is needed to examine the relationship between antipsychotic adherence and adherence to diabetes medication and treatment and, most important, whether changes in antipsychotic adherence over time are associated with changes in diabetes treatment engagement and preventable diabetes hospitalization. In addition, understanding whether these relationships persist for individuals with different levels of disease severity, such as those with prior diabetes hospitalizations or more severe complications, may help inform future interventions. It is also worth exploring whether antipsychotic adherence in schizophrenia is associated with improved health outcomes for other ambulatory care sensitive conditions (32, 33). Engagement in mental health treatment may be a critical path toward improving health disparities for individuals with schizophrenia.
Among individuals with prevalent schizophrenia and diabetes, we found that those with very low to no engagement in antipsychotic treatment were the largest group and had the highest risk of a diabetes-related hospitalization. This work extends a previous report that examined diabetes complications in Taiwan using individuals with no antipsychotic medications (medication possession ratio=0) as the reference group (17). These individuals have been overlooked in assessments of medication adherence in schizophrenia that require a minimum of two prescriptions filled (23), including the HEDIS measure of adherence to antipsychotic medications for individuals with schizophrenia. Given that this group had the worst outcomes, research and quality studies need to focus on, rather than exclude, this population.
Our findings also indicate that black individuals were more likely than non-black individuals to have a preventable diabetes-related hospitalization, even after the analyses controlled for engagement in antipsychotic treatment. Our results build on prior research, which suggests that in the general population, black individuals have significantly higher rates of preventable diabetes-related hospitalizations compared with non-Hispanic whites (39). Mangurian and colleagues (40) described the double vulnerability for diabetes among black individuals who have schizophrenia and other serious mental illnesses, calling for increased screening and interventions for this population. The current study suggests that although addressing antipsychotic adherence may reduce preventable diabetes hospitalizations, it will not eliminate the health disparity observed for black individuals. Further research is required and needs to consider the multifactorial and long-standing nature of health disparities for this population, including the quality of care delivered, the impact of discrimination, and other social determinants of health (41–44).
Overall, this study suggests that improving engagement in mental health treatment may reduce preventable diabetes hospitalizations and therefore has the potential to yield cost savings. The estimated average cost of a preventable diabetes-related hospitalization in 2010 was $13,200 (26, 45). Individuals with schizophrenia with very low or no engagement in antipsychotic treatment were 2.42 times more likely to have a preventable diabetes-related hospitalization than those who were adherent. Engaging individuals with very low or no engagement in antipsychotic treatment may have the potential to avert an estimated 57% of preventable diabetes-related hospitalizations and associated costs for this subpopulation. In a time when U.S. health care expenditures continue to grow yearly (46), identifying ways to reduce health care costs while improving outcomes is increasingly important.
There were limitations to this work. First, this study was conducted in a large state Medicaid program and may not be generalizable to other populations. Antipsychotic adherence was calculated by using claims and encounter data; any medications not paid by Medicaid (e.g., paid out of pocket or medication samples) were not included. We did not consider hospitalizations in adherence calculations, which may result in an underestimate of adherence for individuals with hospitalizations. This study included both type 1 and type 2 diabetes; further study is needed to investigate the relationship between antipsychotic adherence and preventable diabetes hospitalization by disease type. Finally, this cross-sectional study design identified a relationship between antipsychotic adherence and fewer diabetes-related hospitalizations, but future study is needed to understand causal and temporal relationships, if any, between antipsychotic adherence and preventable diabetes-related hospitalizations.
Conclusions
Among individuals with diabetes and schizophrenia, those who were not adherent to antipsychotic medications were at increased risk of preventable diabetes hospitalizations compared with individuals who were adherent to antipsychotics. However, among those who were antipsychotic adherent, the percentage with a preventable diabetes hospitalization was similar to that of the total diabetes population. An inverse relationship was observed in which preventable hospitalizations were highest among individuals with very low to no antipsychotic engagement (4.7%), followed by those with low to moderate adherence (3.3%) and antipsychotic adherent individuals (2.0%) were comparable with those among the total diabetes population (both 2.0%). Findings also indicated that black individuals in the study population were significantly more likely than individuals of other racial-ethnic minority groups to experience a diabetes-related hospitalization independent of antipsychotic medication adherence.
These results suggest that interventions targeted at improving engagement in mental health treatment for schizophrenia may reduce preventable diabetes hospitalizations. Further research is needed to understand the impact of race-ethnicity on health outcomes among individuals with comorbid diabetes and schizophrenia. Research is also needed to examine the specific mechanisms by which antipsychotic adherence affects health outcomes among individuals with comorbid diabetes and schizophrenia.
Footnotes
Institutional support for this study was provided by the New York State Department of Health and the New York State Office of Mental Health. The authors thank Deborah Layman, M.A., and Katrina Vega, M.S.W. These views represent the opinions of the authors and not necessarily those of the New York State Department of Health or the New York State Office of Mental Health. Examples of analysis performed within this article are only examples and should not be used in real-world analytic products.
The authors report no financial relationships with commercial interests.
References
1.
Weiden PJ, Olfson M: Cost of relapse in schizophrenia. Schizophr Bull 1995; 21:419–429
2.
Eaddy M, Grogg A, Locklear J: Assessment of compliance with antipsychotic treatment and resource utilization in a Medicaid population. Clin Ther 2005; 27:263–272
3.
Knapp M, King D, Pugner K, et al: Non-adherence to antipsychotic medication regimens: associations with resource use and costs. Br J Psychiatry 2004; 184:509–516
4.
Lehman AF, Kreyenbuhl J, Buchanan RW, et al: The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003. Schizophr Bull 2004; 30:193–217
5.
Goff DC, Falkai P, Fleischhacker WW, et al: The long-term effects of antipsychotic medication on clinical course in schizophrenia. Am J Psychiatry 2017; 174:840–849
6.
Guo JJ, Keck PE Jr, Corey-Lisle PK, et al: Risk of diabetes mellitus associated with atypical antipsychotic use among patients with bipolar disorder: a retrospective, population-based, case-control study. J Clin Psychiatry 2006; 67:1055–1061
7.
Newcomer JW, Lieberman JA: Comparing safety and tolerability of antipsychotic treatment. J Clin Psychiatry 2007; 68:e07
8.
Morrato EH, Cuffel B, Newcomer JW, et al: Metabolic risk status and second-generation antipsychotic drug selection: a retrospective study of commercially insured patients. J Clin Psychopharmacol 2009; 29:26–32
9.
Patel JK, Buckley PF, Woolson S, et al: Metabolic profiles of second-generation antipsychotics in early psychosis: findings from the CAFE study. Schizophr Res 2009; 111:9–16
10.
Pillinger T, Beck K, Gobjila C, et al: Impaired glucose homeostasis in first-episode schizophrenia: a systematic review and meta-analysis. JAMA Psychiatry 2017; 74:261–269
11.
Rajkumar AP, Horsdal HT, Wimberley T, et al: Endogenous and antipsychotic-related risks for diabetes mellitus in young people with schizophrenia: a Danish population-based cohort study. Am J Psychiatry 2017; 174:686–694
12.
Cahoon EK, McGinty EE, Ford DE, et al: Schizophrenia and potentially preventable hospitalizations in the United States: a retrospective cross-sectional study. BMC Psychiatry 2013; 13:37
13.
Gunzler D, Sajatovic M, McCormick R, et al: Psychosocial features of clinically relevant patient subgroups with serious mental illness and comorbid diabetes. Psychiatr Serv 2017; 68:96–99
14.
Chwastiak LA, Davydow DS, McKibbin CL, et al: The effect of serious mental illness on the risk of rehospitalization among patients with diabetes. Psychosomatics 2014; 55:134–143
15.
Horvitz-Lennon M, Kilbourne AM, Pincus HA: From silos to bridges: meeting the general health care needs of adults with severe mental illnesses. Health Aff 2006; 25:659–669
16.
Gilmer TP, Dolder CR, Lacro JP, et al: Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry 2004; 161:692–699
17.
Wu CS, Gau SS: Association between antipsychotic treatment and advanced diabetes complications among schizophrenia patients with type 2 diabetes mellitus. Schizophr Bull 2016; 42:703–711
18.
Weinmann S, Read J, Aderhold V: Influence of antipsychotics on mortality in schizophrenia: systematic review. Schizophr Res 2009; 113:1–11
19.
Tiihonen J, Lönnqvist J, Wahlbeck K, et al: 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 2009; 374:620–627
20.
Torniainen M, Mittendorfer-Rutz E, Tanskanen A, et al: Antipsychotic treatment and mortality in schizophrenia. Schizophr Bull 2015; 41:656–663
21.
De Hert M, Correll CU, Cohen D: Do antipsychotic medications reduce or increase mortality in schizophrenia? A critical appraisal of the FIN-11 study. Schizophr Res 2010; 117:68–74
22.
Tiihonen J, Tanskanen A, Taipale H: 20-year nationwide follow-up study on discontinuation of antipsychotic treatment in first-episode schizophrenia. Am J Psychiatry 2018; 175:765–773
23.
HEDIS and Performance Measurement. Washington, DC, National Committee for Quality Assurance. www.ncqa.org/hedis-quality-measurement. Accessed March 3, 2013
24.
Neff JM, Sharp VL, Muldoon J, et al: Identifying and classifying children with chronic conditions using administrative data with the Clinical Risk Group classification system. Ambul Pediatr 2002; 2:71–79
25.
Prevention Quality Indicators Overview. Rockville, MD, Agency for Healthcare Research and Quality. www.qualityindicators.ahrq.gov/modules/pqi_overview.aspx. Accessed Sept 19, 2019
26.
Prevention Quality Indicator v4.5 Benchmark Data Tables. Rockville, MD, Agency for Healthcare Research and Quality, 2013. www.qualityindicators.ahrq.gov/Downloads/Modules/PQI/V45/Version_45_Benchmark_Tables_PQI.pdf. Accessed March 3, 2016
27.
SAS (version 9.4). Cary, NC, SAS Institute, 2003
28.
Helmer DA, Tseng CL, Brimacombe M, et al: Applying diabetes-related Prevention Quality Indicators to a national cohort of veterans with diabetes. Diabetes Care 2003; 26:3017–3023
29.
Diagnostic and Statistical Manual of Mental Disorders, 5th ed. Arlington, VA, American Psychiatric Publishing, 2013
30.
Cohen D, Correll CU: Second-generation antipsychotic-associated diabetes mellitus and diabetic ketoacidosis: mechanisms, predictors, and screening need. J Clin Psychiatry 2009; 70:765–766
31.
De Hert M, Detraux J, van Winkel R, et al: Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol 2011; 8:114–126
32.
Olfson M, Gerhard T, Huang C, et al: Premature mortality among adults with schizophrenia in the United States. JAMA Psychiatry 2015; 72:1172–1181
33.
Miller BJ, Paschall CB III, Svendsen DP: Mortality and medical comorbidity among patients with serious mental illness. Psychiatr Serv 2006; 57:1482–1487
34.
Sajatovic M, Gunzler DD, Kanuch SW, et al: A 60-week prospective RCT of a self-management intervention for individuals with serious mental illness and diabetes mellitus. Psychiatr Serv 2017; 68:883–890
35.
Chwastiak LA, Luongo M, Russo J, et al: Use of a mental health center collaborative care team to improve diabetes care and outcomes for patients with psychosis. Psychiatr Serv 2018; 69:349–352
36.
McGinty EE, Baller J, Azrin ST, et al: Interventions to address medical conditions and health-risk behaviors among persons with serious mental illness: a comprehensive review. Schizophr Bull 2016; 42:96–124
37.
Ayuso-Gutiérrez JL, del Río Vega JM: Factors influencing relapse in the long-term course of schizophrenia. Schizophr Res 1997; 28:199–206
38.
Simpson SH, Eurich DT, Majumdar SR, et al: A meta-analysis of the association between adherence to drug therapy and mortality. BMJ 2006; 333:15
39.
Russo CA, Andrews RM, Coffey RM: Racial and Ethnic Disparities in Potentially Preventable Hospitalizations, 2003: Statistical Brief #10; in Healthcare Cost and Utilization Project (HCUP) Statistical Briefs. Rockville, MD, Agency for Healthcare Research and Quality, 2006
40.
Mangurian C, Keenan W, Newcomer JW, et al: Diabetes prevalence among racial-ethnic minority group members with severe mental illness taking antipsychotics: double jeopardy? Psychiatr Serv 2017; 68:843–846
41.
Fontanarosa PB, Bauchner H: Race, ancestry, and medical research. JAMA 2018; 320:1539–1540
42.
Heisler M, Smith DM, Hayward, RA, et al: Racial disparities in diabetes care processes, outcomes, and treatment intensity. Med Care 2003; 41:1221–1232
43.
Whitaker KM, Everson-Rose SA, Pankow JS, et al: Experiences of discrimination and incident type 2 diabetes mellitus: the Multi-Ethnic Study of Atherosclerosis (MESA). Am J Epidemiol 2017; 186:445–455
44.
Walker RJ, Smalls BL, Campbell JA, et al: Impact of social determinants of health on outcomes for type 2 diabetes: a systematic review. Endocrine 2014; 47:29–48
45.
Torio CM, Elixhauser A, Andrews RM: Trends in Potentially Preventable Hospital Admissions Among Adults and Children, 2005–2010: Statistical Brief #151; in Healthcare Cost and Utilization Project (HCUP) Statistical Briefs. Rockville, MD, Agency for Healthcare Research and Quality, 2013
46.
Statistical Help: Risk (Retrospective). Merseyside, England, Stats Direct Limited, 2018. www.statsdirect.com/help/default.htm#clinical_epidemiology/risk_retrospective.htm. Accessed Sept 19, 2019
Information & Authors
Information
Published In
History
Received: 8 November 2018
Revision received: 12 August 2019
Accepted: 23 August 2019
Published online: 20 November 2019
Published in print: March 01, 2020
Keywords
Authors
Author Contributions
All authors contributed equally to this article.
Metrics & Citations
Metrics
Citations
Export Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.
For more information or tips please see 'Downloading to a citation manager' in the Help menu.
View Options
View options
PDF/EPUB
View PDF/EPUBLogin options
Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.
Personal login Institutional Login Open Athens loginNot a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).